In preclinical models, benfotiamine efficiently ameliorates the clinical and biological pathologies that define Alzheimer’s disease (AD) including impaired cognition, amyloid-β plaques, neurofibrillary tangles, diminished glucose metabolism, oxidative stress, increased advanced glycation end products (AGE), and inflammation.
Objective:
To collect preliminary data on feasibility, safety, and efficacy in individuals with amnestic mild cognitive impairment (aMCI) or mild dementia due to AD in a placebo-controlled trial of benfotiamine.
Methods:
A twelve-month treatment with benfotiamine tested whether clinical decline would be delayed in the benfotiamine group compared to the placebo group. The primary clinical outcome was the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). Secondary outcomes were the clinical dementia rating (CDR) score and fluorodeoxyglucose (FDG) uptake, measured with brain positron emission tomography (PET). Blood AGE were examined as an exploratory outcome.
Results:
Participants were treated with benfotiamine (34) or placebo (36). Benfotiamine treatment was safe. The increase in ADAS-Cog was 43% lower in the benfotiamine group than in the placebo group, indicating less cognitive decline, and this effect was nearly statistically significant (p = 0.125). Worsening in CDR was 77% lower (p = 0.034) in the benfotiamine group compared to the placebo group, and this effect was stronger in the APOEɛ4 non-carriers. Benfotiamine significantly reduced increases in AGE (p = 0.044), and this effect was stronger in the APOEɛ4 non-carriers. Exploratory analysis derivation of an FDG PET pattern score showed a treatment effect at one year (p = 0.002).
Conclusion:
Oral benfotiamine is safe and potentially efficacious in improving cognitive outcomes among persons with MCI and mild AD.
JohnsonECB, DammerEB, DuongDM, PingL, ZhouM, YinL, HigginbothamLA, GuajardoA, WhiteB, TroncosoJC, ThambisettyM, MontineTJ, LeeEB, TrojanowskiJQ, BeachTG, ReimanEM, HaroutunianV, WangM, SchadtE, ZhangB, DicksonDW, Ertekin-TanerN, GoldeTE, PetyukVA, De JagerPL, BennettDA, WingoTS, RangarajuS, HajjarI, ShulmanJM, LahJJ, LeveyAI, SeyfriedNT (2020) Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med26, 769–780.
5.
GibsonGE, SheuK-FR, BlassJP, BakerA, CarlsonKC, HardingB, PerrinoP (1988) Reduced Activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch Neurol45, 836–840.
6.
GibsonGE, HaroutunianV, ZhangH, ParkLCH, ShiQ, LesserM, MohsRC, SheuRKF, BlassJP (2000) Mitochondrial damage in Alzheimer’s disease varies with apolipoprotein E genotype. Ann Neurol48, 297–303.
7.
BubberP, HaroutunianV, FischG, BlassJP, GibsonGE (2005) Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications. Ann Neurol57, 695–703.
8.
KaruppagounderS, GibsonGE (2009) Thiamine deficiency: A model of metabolic encephalopathy and of selective neuronal vulnerability. In Metabolic Encephalopathy, McCandlessDW, ed. SpringerNew York, New York, NY, pp. 235–260.
DerkJ, MacLeanM, JuranekJ, SchmidtAM (2018) The receptor for advanced glycation endproducts (RAGE) and mediation of inflammatory neurodegeneration. J Alzheimers Dis Parkinsonism8, 421.
11.
ChouP-S, WuM-N, YangC-C, ShenC-T, YangY-H (2019) Effect of advanced glycation end products on the progression of Alzheimer’s disease. J Alzheimers Dis72, 191–197.
12.
AtaçZS, AlaylıoğluM, DursunE, Gezen-AkD, YılmazerS, GürvitH (2019) G82S polymorphism of receptor for advanced glycation end products gene and serum soluble RAGE levels in mild cognitive impairment and dementia of Alzheimer’s type patients in Turkish population. J Clin Neurosci59, 197–201.
13.
BalakumarP, RohillaA, KrishanP, SolairajP, ThangathirupathiA (2010) The multifaceted therapeutic potential of benfotiamine. Pharmacol Res61, 482–488.
14.
RajV, OjhaS, HowarthFC, BelfurPD, SubramanyaSB (2018) Therapeutic potential of benfotiamine and its molecular targets. Eur Rev Medl Pharmacol Sci22, 3261–3273.
15.
PekovichSR, MartinPR, SingletonCK (1998) Thiamine deficiency decreases steady-state transketolase and pyruvate dehydrogenase but not α-ketoglutarate dehydrogenase mRNA levels in three human cell types. J Nutr128, 683–687.
16.
AhmedN (2005) Advanced glycation endproducts— role in pathology of diabetic complications. Diabetes Res Clin67, 3–21.
GibsonGE, HirschJA, CirioRT, JordanBD, FonzettiP, ElderJ (2013) Abnormal thiamine-dependent processes in Alzheimer’s Disease. Lessons from diabetes. Mol Cell Neurosci55, 17–25.
19.
GibsonGE, HirschJA, FonzettiP, JordanBD, CirioRT, ElderJ (2016) Vitamin B1 (thiamine) and dementia. Ann NY Acad Sci1367, 21–30.
20.
StrackeH, GausW, AchenbachU, FederlinK, BretzelRG (2008) Benfotiamine in diabetic polyneuropathy (BENDIP): Results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes116, 600–605.
21.
ThornalleyPJ, Babaei-JadidiR, Al AliH, RabbaniN, AntonysunilA, LarkinJ, AhmedA, RaymanG, BodmerCW (2007) High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia50, 2164–2170.
El-HattabAW, ZaranteAM, AlmannaiM, ScagliaF (2017) Therapies for mitochondrial diseases and current clinical trials. Mol Genet Metab122, 1–9.
24.
SchmidU, StopperH, HeidlandA, SchuppN (2008) Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev24, 371–377.
25.
GorlovaA, PavlovD, AnthonyDC, PonomarevED, SambonM, ProshinA, ShafarevichI, BabaevskayaD, LeschK-P, BettendorffL, StrekalovaT (2019) Thiamine and benfotiamine counteract ultrasound-induced aggression, normalize AMPA receptor expression and plasticity markers, and reduce oxidative stress in mice. Neuropharmacology156, 107543.
26.
SambonM, NappA, DemelenneA, VignisseJ, WinsP, FilletM, BettendorffL (2019) Thiamine and benfotiamine protect neuroblastoma cells against paraquat and β-amyloid toxicity by a coenzyme-independent mechanism. Heliyon5, e01710.
ShoebM, RamanaKV (2012) Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic Biol Med52, 182–190.
TapiasV, JainuddinS, AhujaM, StackC, ElipenahliC, VignisseJ, GergesM, StarkovaN, XuH, StarkovAA, BettendorffL, HushpulianDM, SmirnovaNA, GazaryanIG, KaideryNA, WakadeS, CalingasanNY, ThomasB, GibsonGE, DumontM, BealMF (2018) Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Hum Mol Genet27, 2874–2892.
31.
PanX, GongN, ZhaoJ, YuZ, GuF, ChenJ, SunX, ZhaoL, YuM, XuZ, DongW, QinY, FeiG, ZhongC, XuT-L (2010) Powerful beneficial effects of benfotiamine on cognitive impairment and β-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain133, 1342–1351.
32.
MarkovaN, BazhenovaN, AnthonyDC, VignisseJ, SvistunovA, LeschK-P, BettendorffL, StrekalovaT (2017) Thiamine and benfotiamine improve cognition and ameliorate GSK-3β-associated stress-induced behaviours in mice. Prog Neuropsychopharmacol75, 148–156.
33.
VignisseJ, SambonM, GorlovaA, PavlovD, CaronN, MalgrangeB, ShevtsovaE, SvistunovA, AnthonyDC, MarkovaN, BazhenovaN, CoumansB, LakayeB, WinsP, StrekalovaT, BettendorffL (2017) Thiamine and benfotiamine prevent stress-induced suppression of hippocampal neurogenesis in mice exposed to predation without affecting brain thiamine diphosphate levels. Mol Cell Neurosci82, 126–136.
34.
HaddadM, PerrotteM, LandriS, LepageA, FülöpT, RamassamyC (2019) Circulating and extracellular vesicles levels of N-(1-Carboxymethyl)-L-Lysine (CML) differentiate early to moderate Alzheimer’s disease. J Alzheimers Dis69, 751–762.
35.
HaddadM, PerrotteM, KhedherMRB, DemonginC, LepageA, FülöpT, RamassamyC (2019) Methylglyoxal and glyoxal as potential peripheral markers for MCI diagnosis and their effects on the expression of neurotrophic, inflammatory and neurodegenerative factors in neurons and in neuronal derived-extracellular vesicles. Int J Mol Sci20, 4906.
36.
PanX, ChenZ, FeiG, PanS, BaoW, RenS, GuanY, ZhongC (2016) Long-term cognitive improvement after benfotiamine administration in patients with Alzheimer’s disease. Neurosi Bull32, 591–596.
37.
StirbanA, NegreanM, StratmannB, GawlowskiT, HorstmannT, GöttingC, KleesiekK, Mueller-RoeselM, KoschinskyT, UribarriJ, VlassaraH, TschoepeD (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care29, 2064–2071.
RockwoodK, FayS, GormanM, CarverD, GrahamJE (2007) The clinical meaningfulness of ADAS-Cog changes in Alzheimer’s disease patients treated with donepezil in an open-label trial. BMC Neurol7, 26.
40.
TariotPN, SolomonPR, MorrisJC, KershawP, LilienfeldS, DingC (2000) A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology54, 2269.
41.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
42.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCR, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
43.
GangolfM, CzernieckiJ, RadermeckerM, DetryO, NisolleM, JouanC, MartinD, ChantraineF, LakayeB, WinsP, GrisarT, BettendorffL (2010) Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells. PLoS One5, e13616–e13616.
44.
DoraiswamyPM, SperlingRA, ColemanRE, JohnsonKA, ReimanEM, DavisMD, GrundmanM, SabbaghMN, SadowskyCH, FleisherAS, CarpenterA, ClarkCM, JoshiAD, MintunMA, SkovronskyDM, PontecorvoMJ (2012) Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurol79, 1636–1644.
45.
BalsisS, UngerAA, BengeJF, GeraciL, DoodyRS (2012) Gaining precision on the Alzheimer’s Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scores. Alzheimers Dement8, 288–294.
46.
WeyerG, ErzigkeitH, KanowskiS, IhlR, HadlerD (1997) Alzheimer’s Disease Assessment Scale: Reliability and validity in a multicenter clinical trial. Int Psychogeriatr9, 123–138.
47.
HughesCP, BergL, DanzigerW, CobenLA, MartinRL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry140, 566–572.
48.
BuschkeH, FuldPA (1974) Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology24, 1019.
49.
FuldPA, BuschkeH (1976) Stages of retrieval in verbal learning. J Verb Learning Verb Behav15, 401–410.
50.
SliwinskiM, BuschkeH, StewartWF, MasurD, LiptonRB (1997) The effect of dementia risk factors on comparative and diagnostic selective reminding norms. J Intl Neuropsychol Soc3, 317–326.
51.
CummingsJL (1997) The Neuropsychiatric Inventory.10S. Neurology48.
52.
CummingsJ (2020) The Neuropsychiatric Inventory: Development and applications. J Geriatr Psychiatry Neurol33, 73–84.
53.
CummingsJL, McPhersonS (2001) Neuropsychiatric assessment of Alzheimer’s disease and related dementias. Aging Clin Exp Res13, 240–246.
54.
GalaskoD, BennettD, SanoM, ErnestoC, ThomasR, GrundmanM, FerrisS (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzheimer Dis Assoc Disord11, S33–S39.
55.
GalaskoD, BennettDA, SanoM, MarsonD, KayeJ, EdlandSD, Alzheimer’s Disease Cooperative Study (2006) ADCS Prevention Instrument Project: Assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord20, S152–S169.
56.
Tzourio-MazoyerN, LandeauB, PapathanassiouD, CrivelloF, EtardO, DelcroixN, MazoyerB, JoliotM (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage15, 273–289.
57.
MoellerJR, StrotherSC, SidtisJJ, RottenbergDA (1987) Scaled subprofile model: A statistical approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab7, 649–658.
58.
StrotherSC, AndersonJR, SchaperKA, SidtisJJ, LiowJS, WoodsRP, RottenbergDA (1995) Principal component analysis and the scaled subprofile model compared to intersubject averaging and statistical parametric mapping: I. “Functional connectivity” of the human motor system studied with [15O]water PET. J Cereb Blood Flow Metab15, 738–753.
59.
HabeckC, FosterNL, PerneczkyR, KurzA, AlexopoulosP, KoeppeRA, DrzezgaA, SternY (2008) Multivariate and univariate neuroimaging biomarkers of Alzheimer’s disease. Neuroimage40, 1503–1515.
60.
HabeckC, SternY, Alzheimer’s Disease Neuroimaging Initiative (2010) Multivariate data analysis for neuroimaging data: Overview and application to Alzheimer’s disease. Cell Biochem Biophys58, 53–67.
61.
HabeckCG (2010) Basics of multivariate analysis in neuroimaging data. J Vis Exp, 1988.
62.
BurnhamKP, AndersonDR, BurnhamKP (2002) Model selection and multimodel inference a practical information-theoretic approach. Springer, New York.
63.
EfronB (1982) The jackknife, the bootstrap, and other resampling plans. Society for Industrial and Applied Mathematics, Philadelphia.
64.
EfronB, TibshiraniR (1993) An introduction to the bootstrap, Chapman & Hall, New York.
65.
HonigLS, VellasB, WoodwardM, BoadaM, BullockR, BorrieM, HagerK, AndreasenN, ScarpiniE, Liu-SeifertH, CaseM, DeanRA, HakeA, SundellK, Poole HoffmannV, CarlsonC, KhannaR, MintunM, DeMattosR, SelzlerKJ, SiemersE (2018) Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med378, 321–330.
66.
MolnarFJ, HuttonB, FergussonD (2008) Does analysis using “last observation carried forward” introduce bias in dementia research?Can Med Assoc J179, 751.
MolinaJA, Jiménez-JiménezFJ, HernánzA, Fernández-VivancosE, MedinaS, de BustosF, Gómez-EscalonillaC, SayedY (2002) Cerebrospinal fluid levels of thiamine in patients with Alzheimer’s disease. J Neural Transm109, 1035–1044.
69.
GlasøM, NordbøG, DiepL, BøhmerT (2004) Reduced concentrations of several vitamins in normal weight patients with late-onset dementia of the Alzheimer type without vascular disease. J Nutr Health Aging8, 407–413.
MezhenskaOA, AleshinVA, KaehneT, ArtiukhovAV, BunikVI (2020) Regulation of malate dehydrogenases and glutamate dehydrogenase of mammalian brain by thiamine in vitro and in vivo. Biochemistry (Mosc)85, 27–39.
72.
GibsonGE, BlassJP (2007) Thiamine-dependent processes and treatment strategies in neurodegeneration. Antioxid Redox Signal9, 605–1620.
73.
MkrtchyanG, AleshinV, ParkhomenkoY, KaehneT, Luigi Di SalvoM, ParroniA, ContestabileR, VovkA, BettendorffL, BunikV (2015) Molecular mechanisms of the non-coenzyme action of thiamin in brain: Biochemical, structural and pathway analysis. Sci Rep5, 12583.
74.
Von MuraltA (1958) The role of thiamine (vitamin B1) in nervous excitation. Exp Cell Res14, 72–79.
75.
JansenWJ, OssenkoppeleR, KnolDL, TijmsBM, ScheltensP, VerheyFRJ, VisserPJ, and the Amyloid Biomarker Study G (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA313, 1924–1938.
76.
SchmechelDE, SaundersAM, StrittmatterWJ, CrainBJ, HuletteCM, JooSH, Pericak-VanceMA, GoldgaberD, RosesAD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A90, 9649–9653.
77.
RebeckGW, ReiterJS, StricklandDK, HymanBT (1993) Apolipoprotein E in sporadic Alzheimer’s disease: Allelic variation and receptor interactions. Neuron11, 575–580.
78.
DeoP, DhillonVS, ChuaA, ThomasP, FenechM (2019) APOE ɛ4 carriers have a greater propensity to glycation and sRAGE which is further influenced by RAGE G82S polymorphism. J Gerontol A Biol75, 1899–1905.
79.
MeliM, PerierC, FerronC, ParssegnyF, DenisC, GonthierR, LaurentB, ReynaudE, FreyJ, ChamsonA (2002) Serum pentosidine as an indicator of Alzheimer’s disease. J Alzheimers Dis4, 93–96.
